BMSSC
ATRA icon

B. Metzler seel. Sohn & Co’s Atara Biotherapeutics ATRA Stock Holding History

B. Metzler seel. Sohn & Co’s Portfolio ATRA Stock Details ATRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-1,971
Closed -$72.9K – 753
2023
Q3 		$72.9K Sell
1,971
-1,972
-50% -$87.8K ﹤0.01% 721
2023
Q2 		$159K Buy
3,943
+1,972
+100% +$112K ﹤0.01% 728
2023
Q1 		$143K Hold
1,971
– – ﹤0.01% 721
2022
Q4 		$162K Buy
1,971
+372
+23% +$38.8K ﹤0.01% 711
2022
Q3 		$151K Buy
1,599
+954
+148% +$107K ﹤0.01% 722
2022
Q2 		$126K Buy
+645
New +$105K ﹤0.01% 715

Other funds holding ATRA

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

B. Metzler seel. Sohn & Co's ATRA Position: Q4 2023 in Review

B. Metzler seel. Sohn & Co sold out of Atara Biotherapeutics (ATRA) in Q4 2023, closing a stake of 1,971 shares — an estimated $72.9K sold.

B. Metzler seel. Sohn & Co first reported a position in ATRA in Q2 2022 and held it in 6 quarters. The position peaked at $162K in Q4 2022. 89 funds tracked by Wall St. Rank hold ATRA as of Q4 2023.

  • B. Metzler seel. Sohn & Co reported no remaining Atara Biotherapeutics position as of Q4 2023 after selling out during the quarter.
  • B. Metzler seel. Sohn & Co sold 1,971 Atara Biotherapeutics shares in Q4 2023, an estimated $72.9K.
  • B. Metzler seel. Sohn & Co first reported a position in Atara Biotherapeutics in Q2 2022 and held it in 6 quarters.
  • B. Metzler seel. Sohn & Co's Atara Biotherapeutics position peaked at $162K in Q4 2022.
  • 89 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q4 2023.

Based on B. Metzler seel. Sohn & Co's 13F filing for Q4 2023, filed 13 Feb 2024.